REN and diabetic kidney disease: For decades, inhibition of the renin-angiotensin-aldosterone system (RAAS) with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ARBs) formed the cornerstone of therapy to slow CKD progression and reduce CV risk in DKD [4].